Literature DB >> 25054050

Osteosarcoma with metastasis at initial diagnosis: Current outcomes and prognostic factors in the context of a comprehensive cancer center.

Samer Salah1, Rami Ahmad1, Iyad Sultan2, Sameer Yaser1, Ahmad Shehadeh3.   

Abstract

The aim of this study was to report the outcomes and prognostic factors for a cohort of patients with osteosarcoma who presented with metastasis at initial diagnosis. Data of consecutive patients with osteosarcoma and metastatic disease at initial presentation, who were treated and followed up at a single institution, were retrospectively reviewed. The effect of potential factors on overall survival (OS) was analyzed through univariate and multivariate analysis. Between January, 2000 and March, 2013, a total of 135 patients with osteosarcoma, of whom 21 (16.0%) had distant metastasis at initial presentation, were diagnosed and treated at our center and were included in this analysis. The patients were treated with a strategy that integrates multi-agent chemotherapy and resection of all sites of gross disease whenever feasible. The 5-year OS and event-free survival (EFS) were 23.0% and 11.0%, respectively. The factors associated with inferior OS in the univariate analysis included the osteoblastic variant, extrapulmonary metastasis and failure to achieve complete remission. In the multivariate analysis, the osteoblastic variant [hazard ratio (HR)=4.83, 95% confidence interval (CI): 1.16-20.0, P=0.038] and extrapulmonary metastasis (HR=5.0, 95% CI: 1.40-17.94, P=0.018) were the only independent prognostic factors. The current outcomes of patients with osteosarcoma and metastasis at initial diagnosis remained poor. The osteoblastic subtype and extrapulmonary metastatic sites predicted poor survival in our series. To the best of our knowledge, this is the first report of the correlation between the histological subtype and survival for patients with metastatic disease at initial presentation; therefore, confirmation in future studies is required.

Entities:  

Keywords:  chemotherapy; metastasis; osteosarcoma; overall survival; prognostic factors

Year:  2014        PMID: 25054050      PMCID: PMC4106734          DOI: 10.3892/mco.2014.325

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  17 in total

1.  Osteosarcoma in the first decade of life.

Authors:  Rajaram Nagarajan; Brenda J Weigel; Roby C Thompson; John P Perentesis
Journal:  Med Pediatr Oncol       Date:  2003-11

Review 2.  The therapy of osteogenic sarcoma: current status and thoughts for the future.

Authors:  M A Friedman; S K Carter
Journal:  J Surg Oncol       Date:  1972       Impact factor: 3.454

3.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

4.  Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Authors:  Sarah E S Leary; Amy W Wozniak; Catherine A Billups; Jianrong Wu; Valerie McPherson; Michael D Neel; Bhaskar N Rao; Najat C Daw
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

5.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.

Authors:  Stefano Ferrari; Antonio Briccoli; Mario Mercuri; Franco Bertoni; Piero Picci; Amelia Tienghi; Adalberto Brach Del Prever; Franca Fagioli; Alessandro Comandone; Gaetano Bacci
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study.

Authors:  M P Link; A M Goorin; M Horowitz; W H Meyer; J Belasco; A Baker; A Ayala; J Shuster
Journal:  Clin Orthop Relat Res       Date:  1991-09       Impact factor: 4.176

7.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.

Authors:  Leo Kager; Andreas Zoubek; Ulrike Pötschger; Ulrike Kastner; Silke Flege; Beate Kempf-Bielack; Detlev Branscheid; Rainer Kotz; Mechthild Salzer-Kuntschik; Winfried Winkelmann; Gernot Jundt; Hartmut Kabisch; Peter Reichardt; Heribert Jürgens; Helmut Gadner; Stefan S Bielack
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

8.  Prognostic factors in pulmonary metastasized high-grade osteosarcoma.

Authors:  Emilie P Buddingh; Jakob K Anninga; Michel I M Versteegh; Antonie H M Taminiau; R Maarten Egeler; Catherina S P van Rijswijk; Pancras C W Hogendoorn; Arjan C Lankester; Hans Gelderblom
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

9.  Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis.

Authors:  N M Marina; C B Pratt; B N Rao; S J Shema; W H Meyer
Journal:  Cancer       Date:  1992-12-01       Impact factor: 6.860

10.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  15 in total

1.  Osteosarcoma of the Right Lower Femur With Breast and Axillary Lymph Node Metastasis: A Rare Case Presentation.

Authors:  Bijayalaxmi Sahoo; Sandip Barik; Sujata Naik; Saroj Kumar Das Majumdar; Dillip Kumar Parida
Journal:  Cureus       Date:  2021-12-29

2.  Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft models.

Authors:  Xuan Yin Chen; Hui Bing Ruan; Xin Hua Long; Ai Fen Peng; Long Dian Zhou; Jia Ming Liu; Yang Zhou; Zhi Li Liu
Journal:  Exp Ther Med       Date:  2017-03-29       Impact factor: 2.447

3.  Initial diagnostic management of pediatric bone tumors.

Authors:  Rodrigo B Interiano; Alpin D Malkan; Amos H P Loh; Nathan Hinkle; Fazal N Wahid; Armita Bahrami; Shenghua Mao; Jianrong Wu; Michael W Bishop; Michael D Neel; Robert E Gold; Bhaskar N Rao; Andrew M Davidoff; Israel Fernandez-Pineda
Journal:  J Pediatr Surg       Date:  2016-03-02       Impact factor: 2.545

4.  Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis.

Authors:  Xiaodong Bai; Hai Meng; Lifeng Ma; Ai Guo
Journal:  Oncol Lett       Date:  2014-12-11       Impact factor: 2.967

5.  Pathological fractures in predicting clinical outcomes for patients with osteosarcoma.

Authors:  Lien-Hsiang Chung; Po-Kuei Wu; Cheng-Fong Chen; Hung-Kai Weng; Tain-Hsiung Chen; Wei-Ming Chen
Journal:  BMC Musculoskelet Disord       Date:  2016-12-28       Impact factor: 2.362

6.  A review of the mechanism of action and clinical applications of sorafenib in advanced osteosarcoma.

Authors:  James Coventon
Journal:  J Bone Oncol       Date:  2017-08-04       Impact factor: 4.072

7.  Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression.

Authors:  Jing Guo; Ling Min Kong; Ai Fen Peng; Xin Hua Long; Yang Zhou; Yong Shu
Journal:  Mol Med Rep       Date:  2016-10-27       Impact factor: 2.952

8.  TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma.

Authors:  Yanling Tao; Meiyun Xin; Huanchen Cheng; Zongxuan Huang; Tiantian Hu; Teng Zhang; Jianlong Wang
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

9.  Metastatic Osteosarcoma to the Breast Presenting as a Densely Calcified Mass on Mammography.

Authors:  Jonghyeon Kim; Ha Young Woo; Eun-Kyung Kim; Min Jung Kim; Hee Jung Moon; Jung Hyun Yoon
Journal:  J Breast Cancer       Date:  2016-03-25       Impact factor: 3.588

10.  The Curcumin Analog CH-5 Exerts Anticancer Effects in Human Osteosarcoma Cells via Modulation of Transcription Factors p53/Sp1.

Authors:  Felipe Teixeira Lima; Viviane Seba; Gabriel Silva; Guilherme Silva Torrezan; Carlos Roberto Polaquini; Vitor Caressato Pinhanelli; Seung J Baek; Ana Lúcia Fachin; Luis Octavio Regasini; Mozart Marins
Journal:  Int J Mol Sci       Date:  2018-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.